Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion
about
Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virusAntiviral effects of an iminosugar derivative on flavivirus infectionsImino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agentsα-Glucosidase inhibitors as potential broad based anti-viral agentsAnalysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus.Hijacking of host calreticulin is required for the white spot syndrome virus replication cycle.Role of N-oligosaccharide endoplasmic reticulum processing reactions in glycoprotein folding and degradationGlycoproteins: rapid sequencing technology for N-linked and GPI anchor glycans.Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme.Modification of the hepatitis B virus envelope protein glycosylation pattern interferes with secretion of viral particles, infectivity, and susceptibility to neutralizing antibodies.Hepatitis B small surface antigen particles are octahedral.Structure-activity relationship of a new class of anti-hepatitis B virus agents.Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.Role of N glycosylation of hepatitis B virus envelope proteins in morphogenesis and infectivity of hepatitis delta virusIminosugars Inhibit Dengue Virus Production via Inhibition of ER Alpha-Glucosidases--Not Glycolipid Processing Enzymes.The interplay between folding-facilitating mechanisms in Trypanosoma cruzi endoplasmic reticulum.Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis d virus.Hepatitis B virus upregulates host expression of α-1,2-mannosidases via the PPARα pathway.Host factors involved in hepatitis B virus maturation, assembly, and egress.Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors.Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles.Molecular mechanisms underlying HBsAg negativity in occult HBV infection.Iminosugar antivirals: the therapeutic sweet spot.Novel function of the endoplasmic reticulum degradation-enhancing α-mannosidase-like proteins in the human hepatitis B virus life cycle, mediated by the middle envelope protein.Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus.Long-term suppression of hepatitis B virus replication by short hairpin RNA expression using the scaffold/matrix attachment region-based replicating vector system pEPI-1.Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion.Inhibition of cellular alpha-glucosidases results in increased presentation of hepatitis B virus glycoprotein-derived peptides by MHC class I.Posttranslational N-glycosylation of the hepatitis B virus large envelope protein.Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus.Hepatitis B virus subviral envelope particle morphogenesis and intracellular trafficking.alpha-Glucosidase inhibitors have a prolonged antiviral effect against hepatitis B virus through the sustained inhibition of the large and middle envelope glycoproteins.The use of calnexin and calreticulin by cellular and viral glycoproteins.Imino sugars that are less toxic but more potent as antivirals, in vitro, compared with N-n-nonyl DNJ.Preparation, biochemical characterization and biological properties of radiolabelled N-alkylated deoxynojirimycins.Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2.The solution NMR structure of glucosylated N-glycans involved in the early stages of glycoprotein biosynthesis and folding.Determining the structure of oligosaccharides N- and O-linked to glycoproteins.
P2860
Q27469853-82DB7ED7-F756-4B3F-8C42-D67C603E914CQ27472863-93126F62-143B-475E-B252-6B79ECC654F2Q27478192-115E02B0-B172-4353-A087-81F0230E2764Q29036682-2D2D3A1B-3516-4B2E-9DE5-9F782B3898B3Q30671216-58C2E8E8-BD50-4BFA-9026-1553524F7BDEQ33900228-683BDD8D-DB3F-4D0D-9E8A-42C232226445Q33905603-9F8BA014-CD2E-4AE5-BE43-DD6291D9C1E4Q33923384-FE90F57A-C2AB-439A-9193-DD0363D791F1Q34045589-5183FA58-2949-4715-8D61-3CA17E369FD2Q34059278-D87EF8E1-BEEE-4320-8E2C-8ED5ADA25B58Q34078427-99F2AED8-DDDF-4407-BE7F-178CE1D65B53Q34251931-B72C78FE-A540-4BD1-8C23-D209B952A170Q34534466-FF0B5529-03DA-4D1C-89A2-48550018F1A6Q34976217-6DF34A27-852D-4AB6-84FA-E70061EEBB14Q35956223-CB2A06F3-0B87-47B6-937D-6163E3DD74F1Q35973101-7B0A3593-C50C-4B9E-8CE8-D6E287D1E2D2Q36281860-96F6119E-03F1-4A5D-AB56-B99E394AC546Q36483922-62FDCC68-F80C-42CA-9FA3-B2764CEFB7D8Q37424725-9ED45FE4-D92B-4AFB-8C49-4D7843AB6F99Q38042329-521CD8B7-40A0-419D-B2BC-09A6B8964F13Q38151881-2ECD6EDC-093D-47A5-83B8-1DAE04531ADEQ38341008-86FE1C53-6D14-4745-AADE-ABF0ACD710E2Q38536404-88B3A4AA-120B-42CC-9C77-9333798408BDQ38730551-AFAF5645-3DD3-4951-9DCE-C283B80EAD6BQ38753899-78537B09-A08F-46C2-8BF8-706AE312BFC4Q38867984-43888C4E-4E6D-4F73-8273-9F15B1A56B38Q39583127-3F014557-7453-4BF5-AFAD-40ADCB56A3A5Q39686882-3D4A2170-2E8A-45C8-A2C3-96D8398E52CAQ39808366-A92AC120-96FA-4928-A0FB-7DCD74E419B0Q39904096-3B58B954-8E5A-4F3C-8708-9B35BFA6864CQ40126325-17E38ECC-3F76-44BB-97B5-C4491EC9FF2CQ40160028-383CEEA2-D4E7-4D62-BA14-DF5FB3D901EFQ40176615-0CA7B6A1-F131-4052-A40B-D286290571A2Q40193811-07F04707-D4B8-4352-B9D8-F3C82F6B90DDQ40410568-2AC21845-688D-4104-85C6-302A2A2DF74CQ40664872-12C5D168-8435-4524-A694-FF507DFDAED6Q40735193-E117EFE7-5F39-4E88-A65D-31496023D288Q41687420-AE5EF2AD-FB45-4D87-9F3F-DFDC7224366AQ42042274-F465FB50-C12B-4844-BF31-70DAB6795B4DQ42169895-0ADFAFF6-D677-4ACC-B2FF-8BE1586252EE
P2860
Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Hepatitis B virus (HBV) envelo ...... ite can regulate HBV secretion
@ast
Hepatitis B virus (HBV) envelo ...... ite can regulate HBV secretion
@en
type
label
Hepatitis B virus (HBV) envelo ...... ite can regulate HBV secretion
@ast
Hepatitis B virus (HBV) envelo ...... ite can regulate HBV secretion
@en
prefLabel
Hepatitis B virus (HBV) envelo ...... ite can regulate HBV secretion
@ast
Hepatitis B virus (HBV) envelo ...... ite can regulate HBV secretion
@en
P2093
P2860
P356
P1476
Hepatitis B virus (HBV) envelo ...... ite can regulate HBV secretion
@en
P2093
P2860
P304
P356
10.1073/PNAS.94.5.1822
P407
P577
1997-03-01T00:00:00Z